Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Oncology · Esophageal Adenocarcinoma

Symptoms & Risk Factors: Why Did This Happen?

At a Glance

Esophageal adenocarcinoma (EAC) is linked to Barrett's esophagus but can develop without heartburn due to visceral obesity, metabolic syndrome, or silent reflux. Common symptoms include difficulty swallowing, unexplained weight loss, early fullness, and persistent cough.

It is a common misconception that esophageal adenocarcinoma (EAC) and esophagogastric junction (EGJ) adenocarcinoma only happen to people with a long history of severe heartburn. While chronic acid reflux is a major factor, researchers now understand that this cancer is the result of a complex interplay of biology, environment, and metabolism [1][2]. Understanding these factors can help remove the “blame” often felt after a diagnosis and provide clarity on how the disease developed.

The Barrett’s Connection

The most well-known pathway to EAC begins with Barrett’s esophagus. This is a condition where the normal lining of the esophagus changes to look more like the lining of the intestine [3]. This change is the body’s way of trying to protect itself from stomach acid, but the new cells are unstable.

The progression from Barrett’s to cancer is a multi-step biological journey:

  1. Metaplasia: Normal cells become Barrett’s cells.
  2. Dysplasia: The Barrett’s cells develop “precancerous” changes (low-grade or high-grade) [4].
  3. Adenocarcinoma: Genetic changes, such as chromosomal instability, allow these cells to grow uncontrollably and invade deeper tissues [5][6].

Why It Happens Without Heartburn

Surprisingly, many people diagnosed with EAC have no history of significant reflux symptoms [7][8]. This occurs because several risk factors work independently of acid reflux:

  • Visceral Obesity: Carrying weight around the midsection (the “apple” shape) is a powerful independent risk factor [2]. This fat, known as visceral fat, is biologically active. It releases inflammatory chemicals and growth factors that can promote cancer even if acid never reaches the esophagus [9][10].
  • Metabolic Syndrome & Diabetes: Conditions like high blood sugar and insulin resistance create a systemic environment of chronic inflammation [11][12]. This environment can encourage cells at the EGJ to undergo the dangerous changes that lead to cancer [13].
  • “Silent” Reflux: Some people experience reflux without the burning sensation of heartburn. This “silent” reflux can still damage the esophageal lining over many years without the person ever knowing [14].

Other Key Risk Factors

While lifestyle factors play a role, biological and demographic factors that are beyond your control also significantly influence risk:

  • Sex: Men are significantly more likely to develop EAC than women [1][15].
  • Age: The risk increases as we get older, with most diagnoses occurring after age 50 [1].
  • Race: In Western populations, EAC is most common among White individuals [1][16].
  • Smoking: Tobacco use is a major risk factor, as the chemicals in smoke can damage the DNA of the esophageal lining [1][2].

Common Symptoms to Recognize

Early-stage EAC often has no symptoms at all. As the tumor grows, it may cause:

  • Dysphagia: Difficulty swallowing, which often starts with solid foods (like meat or bread) feeling “stuck” [17].
  • Unexplained Weight Loss: This can occur due to changes in metabolism or because eating becomes uncomfortable.
  • Early Satiety: Feeling full very quickly after eating only a small amount of food.
  • Persistent Cough or Hoarseness: Often caused by irritation from “silent” reflux or the tumor’s location.

If you are experiencing these symptoms, it is not because of “eating badly” or a lack of willpower. It is the result of a biological process that your medical team is now ready to address [18].

Common questions in this guide

Can I get esophageal adenocarcinoma without having heartburn?
Yes, many people diagnosed with esophageal adenocarcinoma have no history of severe acid reflux. Risk factors like visceral obesity, metabolic syndrome, and silent reflux can promote cancer development without causing traditional heartburn symptoms.
What is the connection between Barrett's esophagus and cancer?
Barrett's esophagus is a condition where the normal esophageal lining changes to resemble the intestine, often to protect against stomach acid. Over time, these unstable cells can develop precancerous changes called dysplasia, which can eventually progress to cancer.
What are the early signs of esophageal adenocarcinoma?
Early-stage esophageal cancer often has no symptoms. As a tumor grows, you might experience difficulty swallowing solid foods, unexplained weight loss, feeling full quickly after eating small amounts, or a persistent cough and hoarseness.
Does my weight or metabolism affect my risk for esophageal cancer?
Yes, carrying excess visceral fat around the midsection is a strong independent risk factor. This biologically active fat releases inflammatory chemicals that can promote cancer cell growth at the esophagogastric junction, even without acid reflux.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given that I didn't have severe heartburn, what specific factors likely contributed to my diagnosis?
  2. 2.Has my tumor been classified by the 'Siewert' system (Type I, II, or III), and what does that tell us about its origin?
  3. 3.What is the status of my esophagus surrounding the tumor—are there signs of Barrett's esophagus or chronic inflammation?
  4. 4.Do I have any other metabolic health issues, like insulin resistance, that we should manage alongside my cancer treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma.

    Thrift AP, Kendall BJ

    Gastrointestinal endoscopy clinics of North America 2026; (36(1)):49-68 doi:10.1016/j.giec.2025.05.006.

    PMID: 41260772
  2. 2

    Obesity and increased risk of esophageal adenocarcinoma.

    Elliott JA, Donohoe CL, Reynolds JV

    Expert review of endocrinology & metabolism 2015; (10(5)):511-523 doi:10.1586/17446651.2015.1077696.

    PMID: 30298765
  3. 3

    Esophageal Adenocarcinoma: Screening, Surveillance, and Management.

    Mansour NM, Groth SS, Anandasabapathy S

    Annual review of medicine 2017; (68()):213-227 doi:10.1146/annurev-med-050715-104218.

    PMID: 27618753
  4. 4

    Gastroesophageal reflux and Barrett's esophagus: a pathway to esophageal adenocarcinoma.

    Schlottmann F, Molena D, Patti MG

    Updates in surgery 2018; (70(3)):339-342 doi:10.1007/s13304-018-0564-y.

    PMID: 30039277
  5. 5

    Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma.

    Bao C, Tourdot RW, Brunette GJ, et al.

    Nature communications 2023; (14(1)):6203 doi:10.1038/s41467-023-41805-6.

    PMID: 37794034
  6. 6

    Barrett's esophagus stages: their correlation with SBS17-associated DNA mutations and the identification of histological marker genes.

    Busslinger GA

    Molecular & cellular oncology 2022; (9(1)):2026559 doi:10.1080/23723556.2022.2026559.

    PMID: 35252552
  7. 7

    Limitations of Heartburn and Other Societies' Criteria in Barrett's Screening for Detecting De Novo Esophageal Adenocarcinoma.

    Sawas T, Zamani SA, Killcoyne S, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2022; (20(8)):1709-1718 doi:10.1016/j.cgh.2021.10.039.

    PMID: 34757196
  8. 8

    Patients With Esophageal Adenocarcinoma With Prior Gastroesophageal Reflux Disease Symptoms Are Similar to Those Without Gastroesophageal Reflux Disease: A Cross-Sectional Study.

    Chandar AK, Keerthy K, Gupta R, et al.

    The American journal of gastroenterology 2024; (119(5)):823-829 doi:10.14309/ajg.0000000000002593.

    PMID: 37975600
  9. 9

    Visceral Obesity, Metabolic Syndrome, and Esophageal Adenocarcinoma.

    Elliott JA, Reynolds JV

    Frontiers in oncology 2021; (11()):627270 doi:10.3389/fonc.2021.627270.

    PMID: 33777773
  10. 10

    Visceral obesity and incident cancer and cardiovascular disease: An integrative review of the epidemiological evidence.

    Silveira EA, Kliemann N, Noll M, et al.

    Obesity reviews : an official journal of the International Association for the Study of Obesity 2021; (22(1)):e13088 doi:10.1111/obr.13088.

    PMID: 32692447
  11. 11

    Reevaluating Adiponectin's impact on obesity hypertension: a Chinese case-control study.

    Wu O, Lu X, Leng J, et al.

    BMC cardiovascular disorders 2024; (24(1)):208 doi:10.1186/s12872-024-03865-4.

    PMID: 38615012
  12. 12

    [Mutltifaceted biological roles of adiponectin].

    Cuerq C, Morineau G, Dufour-Rainfray D, et al.

    Annales de biologie clinique 2020; (78(3)):243-252 doi:10.1684/abc.2020.1562.

    PMID: 32540813
  13. 13

    The metabolic profile of lean patients with esophageal adenocarcinoma and Barrett's esophagus.

    Sawas T, Benson JT, Allen A, et al.

    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 2025; (38(6)) doi:10.1093/dote/doaf080.

    PMID: 41385385
  14. 14

    Prevalence of Barrett's Esophagus and Esophageal Adenocarcinoma With and Without Gastroesophageal Reflux: A Systematic Review and Meta-analysis.

    Saha B, Vantanasiri K, Mohan BP, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2024; (22(7)):1381-1394.e7 doi:10.1016/j.cgh.2023.10.006.

    PMID: 37879525
  15. 15

    Temporal Trends and Sex Differences in the Incidence of Esophageal Squamous Cell Carcinoma and Adenocarcinoma from CI5 VIII-XII Data - Global, 1993-2017.

    Li J, Sun K, Zhu Q, et al.

    China CDC weekly 2025; (7(15)):491-496 doi:10.46234/ccdcw2025.082.

    PMID: 40375834
  16. 16

    Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma: Implications for Screening and Surveillance.

    Cook MB, Thrift AP

    Gastrointestinal endoscopy clinics of North America 2021; (31(1)):1-26 doi:10.1016/j.giec.2020.08.001.

    PMID: 33213789
  17. 17

    Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma.

    Mitchell KG, Ikoma N, Nelson DB, et al.

    The Annals of thoracic surgery 2019; (108(3)):845-851 doi:10.1016/j.athoracsur.2019.04.024.

    PMID: 31102632
  18. 18

    Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction.

    Zheng YH, Zhao EH

    World journal of gastroenterology 2022; (28(31)):4299-4309 doi:10.3748/wjg.v28.i31.4299.

    PMID: 36159003

This page is for informational purposes only and does not replace professional medical advice. Always consult your oncologist or gastroenterologist about your specific symptoms and risks.

Get notified when new evidence is published on Adenocarcinoma of the oesophagus and oesophagogastric junction.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.